Pharma Pulse: Retatrutide's Black Market Problem, CSafe's Mobile App, BMS's Houston Bet

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast bringing you the latest insights shaping patient access, regulatory policy, and healthcare innovation. I'm your host, and let's get into today's headlines.

First up, Eli Lilly is taking its illicit retatrutide problem to court.

Lilly has filed six lawsuits against US-based medical spas, wellness clinics and suppliers it accuses of marketing black-market versions of retatrutide, its investigational obesity drug.¹ The defendants include Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide, several of which advertise the products as "research use only" while allegedly selling them for human use.² Retatrutide remains in late-phase clinical trials and has not been approved by any regulator; Lilly is expected to submit the drug to FDA for approval by the end of the year.² The company said the knockoffs are frequently supplied by unregulated foreign manufacturers and sold without a prescription, often through websites, social media and businesses presenting themselves as legitimate medical providers.

Lilly chief medical officer David Hyman said in a statement that what's being sold on the black market "is not a medicine," calling it entirely unverified, unapproved and not worth the risk.¹ Beyond the litigation, Lilly said it has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement and professional licensing boards, and has flagged more than 14,000 websites, advertisements and product listings marketing retatrutide across more than 100 countries. The company is also calling on social media platforms, e-commerce companies, payment processors and shipping carriers to help cut off the illicit trade, framing the six new suits as an escalation of a broader enforcement campaign rather than a standalone action. For a manufacturer facing a surging counterfeit and gray-market channel for one of its most closely watched pipeline assets, the case is a preview of the brand-protection fight likely to intensify as retatrutide nears an approval decision.

Next, cold chain teams are getting real-time shipment control outside the desktop.

CSafe has launched the CSafe Connect Mobile App, extending its cloud-based CSafe Connect platform to mobile devices and giving pharmaceutical manufacturers, freight forwarders and airlines real-time access to shipment data, container monitoring and lease management from the warehouse floor, the tarmac, or anywhere else operations take them.³ The platform had previously been tied to desktop access; the mobile app lets users place lease orders, monitor container conditions and GPS location, and pull shipment data on demand without returning to a desk. CSafe is billing it as the first mobile solution of its kind in the pharmaceutical cold chain space, aimed at helping freight forwarders and airline teams respond quickly to shipment irregularities that could otherwise put a temperature-sensitive therapy at risk. CSafe CEO Patrick Schafer said the platform was built to give customers visibility and confidence throughout the shipping journey, and that the mobile app "takes that further by making sure the information they need is available wherever they are, not just at a desk."³

Lastly, reshoring momentum keeps building.

Bristol Myers Squibb will build a $2.3 billion modular manufacturing campus at Houston's Generation Park, part of the company's five-year, $40 billion US investment pledge, and the latest entry in a growing wave of tariff-driven domestic manufacturing announcements. The roughly 600,000-square-foot site is expected to generate nearly 500 skilled jobs and was designed to scale beyond its initial footprint as demand rises, with a modular, multi-modal framework built to run small molecule, biologic and antibody-drug conjugate production side by side rather than dedicating the plant to a single modality. The commitment lands as pharmaceutical manufacturers have pledged roughly $370 billion in domestic manufacturing and research spending over five years, with states actively competing for those dollars, Texas has widened its R&D tax credit and North Carolina is phasing out its corporate income tax to draw the same investment. BMS expects construction and build-out at the Houston site to continue through 2030.

That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.

References

1. Eli Lilly and Company. "Lilly Calls on Online Platforms, Payment Companies and Regulators to Shut Down the Illegal Retatrutide Black Market." Press Release. Aug. 12, 2026. https://investor.lilly.com/news-releases/news-release-details/lilly-calls-online-platforms-payment-companies-and-regulators
2. "Eli Lilly targets alleged black market sales of its experimental GLP-1 drug." The Hill. Published August 12, 2026. https://thehill.com/policy/healthcare/6025205-lilly-targets-illegal-weight-loss-drugs/
3. CSafe. "CSafe Launches Mobile App for CSafe Connect, Bringing Real-Time Shipment Visibility and Control to the Field." Press Release. Aug. 11, 2026. https://hubs.li/Q04sj8GJ0